Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
Dr. Raman has succeeded Victoria Richon
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
More than 2,500 submissions are currently under review in the Food and Drug Administration's (FDA) cell and gene therapy pipeline
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
GOSTAR's proprietary data set underwent rigorous analysis and large-scale ML model building to predict drug solubility in a recent joint study. X-Chem's RosalindAI delivered superior and actionable results than other similar analyses using well-known publically available datasets
The collaboration will leverage EdiGene’s expertise in high-throughput genome editing screening and Neukio’s strength in the development and manufacturing of induced pluripotent stem cell (iPSC) and natural killer cell (NK Cell)
Senior R&D leader from Pfizer and bluebird bio to support Strand’s platform of programmable mRNA-based therapeutics
Subscribe To Our Newsletter & Stay Updated
